Eli Lilly: starts Phase 3 trial on rare cancer drug
(CercleFinance.com) - Eli Lilly on Monday announced the opening of a Phase III clinical trial for selpercatinib for the treatment of medullary thyroid cancer, a rare form of cancer.
Randomized trial will examine selpercatinib against standard of care in 400 patients with advanced or metastatic treatment-naïve RET-mutant medullary thyroid cancer, the US drugmaker said.
This is the second Phase 3 trial to open for selpercatinib, a new investigational drug for the treatment of patients with cancers that harbor abnormalities in the rearranged during transfection (RET) kinase.
Selpercatinib has also received breakthrough designation for lung cancer.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
Randomized trial will examine selpercatinib against standard of care in 400 patients with advanced or metastatic treatment-naïve RET-mutant medullary thyroid cancer, the US drugmaker said.
This is the second Phase 3 trial to open for selpercatinib, a new investigational drug for the treatment of patients with cancers that harbor abnormalities in the rearranged during transfection (RET) kinase.
Selpercatinib has also received breakthrough designation for lung cancer.
Copyright (c) 2019 CercleFinance.com. All rights reserved.